Published in J Urol on November 01, 1997
Acute urinary retention in men: an age old problem. BMJ (1999) 1.36
Acute urinary retention: risks and management. Rev Urol (2005) 0.90
Effect of transurethral resection of the prostate based on the degree of obstruction seen in urodynamic study. Korean J Urol (2013) 0.87
Preoperative Urinary Retention Increased the Risk of Urinary Retention after Photoselective Vaporization of the Prostate. World J Mens Health (2015) 0.83
BPH: predicting TWOC failure in acute urinary retention. Nat Rev Urol (2012) 0.78
Factors affecting de novo urinary retention after Holmium laser enucleation of the prostate. PLoS One (2014) 0.77
Complications of minimally invasive procedures of the abdomen and pelvis: a comprehensive update on the clinical and imaging features. Emerg Radiol (2014) 0.76
Factors affecting trial without catheter for first spontaneous acute urinary retention. Int Neurourol J (2013) 0.75
Relationship of postoperative recatheterization and intraoperative bladder distention volume in holmium laser enucleation of the prostate for benign prostatic hyperplasia. Korean J Urol (2013) 0.75
Surgical treatment of detrusor underactivity: a short term proof of concept study. Int Braz J Urol (2017) 0.75
Transurethral resection of prostate in benign prostatic enlargement with underactive bladder: A retrospective outcome analysis. Urol Ann (2017) 0.75
Can Long-term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention? Curr Urol Rep (2017) 0.75
Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med (1999) 3.38
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol (2001) 2.83
Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU Int (2003) 2.05
Percutaneous stone manipulation. J Urol (1981) 2.00
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol (2000) 1.94
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract (2007) 1.88
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol (1999) 1.86
Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol (1998) 1.73
Is transurethral resection of the prostate still justified? BJU Int (1999) 1.69
Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res (1995) 1.65
A multicenter, double-blind, randomized, parallel group study comparing polyvinyl chloride and polyvinyl chloride-free catheter materials. J Urol (2009) 1.63
High-grade prostate cancer is associated with low serum testosterone levels. Prostate (2001) 1.59
Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest (1992) 1.57
Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn (2000) 1.55
Morbidity of the evaluation of the lower urinary tract with transurethral multichannel pressure-flow studies. J Urol (1998) 1.51
EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol (2001) 1.46
[The testis as eutopic production site of human growth hormone, placental lactogen and prolactin: possible autocrine/paracrine effects on testicular function]. Wien Klin Wochenschr (1996) 1.39
Diagnostic accuracy of DNA image cytometry and urinary cytology with cells from voided urine in the detection of bladder cancer. Urology (2000) 1.38
Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol (1994) 1.26
Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol (1998) 1.21
Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology (1999) 1.18
Morphology of tissue destruction induced by focused ultrasound. Eur Urol (1993) 1.13
Urolithiasis in allograft kidneys. Urology (2002) 1.13
The aging lower urinary tract: a comparative urodynamic study of men and women. Urology (1998) 1.13
Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol (1999) 1.13
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol (2001) 1.11
Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. Br J Urol (1994) 1.11
High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol (1995) 1.10
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol (1997) 1.09
Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol (1998) 1.09
Insulin-like growth factors and prostate cancer. World J Urol (2001) 1.09
Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol (1998) 1.07
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Cross-sectional study of nocturia in both sexes: analysis of a voluntary health screening project. Urology (2000) 1.06
Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate (1998) 1.06
Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem (1996) 1.06
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. Urology (2001) 1.06
Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer (2003) 1.05
PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology (1999) 1.05
Late sequelae of the management of ureteral calculi with the ureterorenoscope. J Urol (1986) 1.05
Interdisciplinary S2e Guideline for the Diagnosis and Treatment of Stress Urinary Incontinence in Women: Short version - AWMF Registry No. 015-005, July 2013. Geburtshilfe Frauenheilkd (2013) 1.04
Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology (2000) 1.03
Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol (1998) 1.02
Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology (1999) 1.00
Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate (2001) 1.00
Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol (1999) 1.00
Transrenal ureteral embolization. Radiology (1979) 0.99
Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer (2001) 0.99
Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate (2001) 0.99
Impact of different sized catheters on pressure-flow studies in patients with benign prostatic hyperplasia. Neurourol Urodyn (1996) 0.98
Transcatheter embolization of the kidney with butyl-2-cyanoacrylate: experimental and clinical results. Cardiovasc Radiol (1978) 0.98
Spontaneous nontraumatic rupture of a contracted kidney with subcapsular and perirenal hematoma in a patient receiving chronic hemodialysis. Urology (1997) 0.98
Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol (1994) 0.98
mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res (2000) 0.98
Interrelationships of bladder compliance with age, detrusor instability, and obstruction in elderly men with lower urinary tract symptoms. Neurourol Urodyn (1999) 0.97
Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology (2003) 0.95
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol (1999) 0.95
Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol (2000) 0.95
Intracavernous injection of prostaglandin E1 in impotent men. J Urol (1988) 0.94
Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms? Br J Urol (1997) 0.92
Modified laparoscopic nephroureterectomy for treatment of upper urinary tract transitional cell cancer is not associated with an increased risk of tumour recurrence. Eur Urol (2003) 0.92
Prostatic tissue ablation by transrectal high intensity focused ultrasound: histological impact and clinical application. Ultrason Sonochem (1997) 0.92
Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol (2004) 0.92
Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology (2001) 0.92
Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev (2001) 0.92
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J Urol (1999) 0.92
Is one set of sextant biopsies enough to rule out prostate Cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol (2000) 0.91
Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology. Eur Urol (2000) 0.91
Intrarenal access: effects on renal function and morphology. Br J Urol (1980) 0.91
Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol (1993) 0.91
Is penile atherosclerosis the link between erectile dysfunction and cardiovascular risk? An autopsy study. Int J Impot Res (2012) 0.91
Health care in Austria. Universal access, national health insurance, and private health care. JAMA (1993) 0.91
Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res (2007) 0.91
Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate. J Urol (1997) 0.90
Laparoscopic surgery in urology. Curr Opin Urol (2000) 0.90
Epidermoid cysts of the testis: organ-preserving surgery following diagnosis by ultrasonography. Br J Urol (1993) 0.89
Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol (2000) 0.89
Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology (2001) 0.89
Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Prostate (1998) 0.89
Stone treatment and coagulopathy. Eur Urol (2003) 0.89
Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol (2000) 0.89
The importance of measuring the prostatic transition zone: an anatomical and radiological study. BJU Int (1999) 0.89